Osprey Medical Inc. PRESERV Clinical Trial Update

2013-06-10
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! MINNEAPOLIS & MELBOURNE, Australia--(BUSINESS WIRE)--Osprey Medical Inc. (ASX: OSP) today announced updates in its PRESERV Clinical Trial, with Dr. Richard Heuser enrolling in May 2013 the first US patients in the PRESERV Clinical Trial at St. Luke’s Medical Center in Phoenix, Arizona. Dr. Heuser is an internationally recognized cardiologist, inventor, educator and author and is one of the early pioneers of the angioplasty procedure. In addition to St. Luke’s Medical Center, twelve additional hospitals have Institutional Review Board (IRB) and contract approval and are actively screening patients for trial enrollment. An additional 25 hospitals are actively pursuing IRB and contract approval. Help employers find you! Check out all the jobs and post your resume.
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。